Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of LY2157299 Monohydrate With or Without Lomustine vs Lomustine in Recurrent Glioblastoma
2011-004418-40Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of galunisertib in glioblastoma (GBM) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Overall survival. Started Jan 2012; status: completed.
02
Drugs
galunisertib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2011-004418-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004418-40.